# William Ware

> William Ware is the co-founder and CEO of DoseOptics LLC, a Dartmouth-affiliated medtech company in Lebanon, New Hampshire that turns a faint blue glow into a safety tool for cancer patients. Its systems image Cherenkov light - the same eerie glow seen in nuclear reactors - to show radiation dose landing on a patient in real time during treatment. A Thayer School of Engineering alumnus with a chemical engineering background, Ware has launched more than 20 patented products across pharmaceuticals, oil and gas, textiles, and medical devices, and partnered DoseOptics with Vision RT to fold Cherenkov imaging into mainstream radiotherapy.

- **Role:** CEO & Co-Founder at DoseOptics LLC
- **Organizations:** DoseOptics LLC, Soane Energy, Nano-Tex, Miltenyi Biotec
- **Nationality:** American
- **Education:** MS, Chemical Engineering, Thayer School of Engineering, Dartmouth College
- **Known for:** Co-founded and leads DoseOptics, pioneering real-time Cherenkov imaging of radiation dose during cancer treatment, Launched more than 20 patented products to commercial success across multiple industries, Secured $3.4M in NIH SBIR funding within one year for DoseOptics

## Career timeline

- **1992-1994** — Earned an MS in Chemical Engineering at Dartmouth's Thayer School of Engineering
- **Pre-2013** — Held executive roles across pharmaceutical, oil and gas, textiles and medical device companies, including Nano-Tex, Miltenyi Biotec and Soane Energy
- **2013** — Co-founded DoseOptics LLC with Thayer professors Brian Pogue and Scott Davis to commercialize Cherenkov imaging for radiotherapy
- **2016** — DoseOptics won a $2M Phase II NIH SBIR grant, reaching $3.4M raised in a single year
- **2024** — Announced long-term partnership with Vision RT; launched DoseRT powered by BeamSite combining Cherenkov imaging with surface-guided radiation therapy

## Achievements

- Co-founded and leads DoseOptics, pioneering real-time Cherenkov imaging of radiation dose during cancer treatment
- Launched more than 20 patented products to commercial success across multiple industries
- Secured $3.4M in NIH SBIR funding within one year for DoseOptics
- Brought BeamSite, an FDA-cleared Cherenkov imaging system, to market
- Forged a long-term partnership with Vision RT to integrate Cherenkov imaging with surface-guided radiation therapy

## Latest updates

- **2024-01** — DoseOptics and Vision RT announced a strategic long-term partnership and the commercial launch of DoseRT powered by BeamSite, integrating Cherenkov imaging with AlignRT Horizon surface guidance.

## Links

- Website: https://doseoptics.com
- LinkedIn: http://www.linkedin.com/in/william-ware-74a372b

---

Profile page: https://yespress.io/william-ware
Published by YesPress — https://yespress.io
Last updated: 2026-06-20